Skip to content

Multicenter Registration Study of Acute Anterior Circulation Large Vessel Occlusive Stroke with Low ASPECTS

Multicenter Registration Study of Acute Anterior Circulation Large Vessel Occlusive Stroke with ASPECTS<6

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000033751
Enrollment
Unknown
Registered
2020-06-11
Start date
2020-06-12
Completion date
Unknown
Last updated
2021-11-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Large vessel occlusion stroke

Interventions

Observation Group:Endovascular treatment

Sponsors

Department of Neurology, Maoming people's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients over 18 years old; 2. The patients with the level of aspects lower than 6 on the plain CT scan; 3. CTA / MRA / DSA confirmed the occlusion of the large vessels (whole internal carotid artery, M1 or M2 middle cerebral artery) in the internal carotid system; 4. Patients whose time from normal to admission (standard drug treatment group) / puncture time (intravascular treatment group) does not exceed 24 hours; 5. Informed consent has been signed by patients or their legal representatives; 6. Subjects and legal representatives are willing to follow up the follow-up requirements of the program.

Exclusion criteria

Exclusion criteria: 1. Patients with Mrs > 2 before onset; 2. Blood glucose 22.2mmol/l; 3. If any of the following exclusion criteria appears in the patient's image, it is not suitable to participate in this study; (1) Preoperative CT or MR showed bleeding symptoms; (2) CT or MR showed intracranial space occupying or tumor requiring surgical treatment; (3) Angiography showed simultaneous acute occlusion of multiple systems in bilateral carotid or basilar arteries. 4. Patients with heart, lung, liver and kidney failure or other serious diseases; 5. Patients with platelet count < 80x10^9/L; 6. Patients with life expectancy less than 3 months; 7. Patients who refuse to sign the consent of relevant research; 8. Select patients who still participate in clinical trials of other drugs or devices within 30 days before the visit.

Design outcomes

Primary

MeasureTime frame
Rate of good neurological function at 90 days (mRS <=3 defined as good prognosis);

Secondary

MeasureTime frame
mRS at 90 days (mRS 0-2);Changes of 24h NCCT ASPECTS after operation;5-7 days CTA/MRA postoperative success rate of recanalization;

Countries

China

Contacts

Public ContactGeng Liao

Department of Neurology, Maoming people's Hospital

legendv@126.com+86 13929703268

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026